Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy

A Phase I Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma

(2021) Di Wang et al.   BLOOD

Entecavir Prophylaxis for Hepatitis B Virus Reactivation in Patients with CAR T-cell Therapy

(2020) Wenyue Cao et al.   BLOOD

How we prevent infections in patients receiving CD19-targeted chimeric antigen receptor T-cells for B-cell malignancies

(2020) Joshua A. Hill et al.   BLOOD

SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity

(2020) Jia Wei et al.   Journal for ImmunoTherapy of Cancer

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR-T – and a side order of IgG, to go? – Immunoglobulin replacement in patients receiving CAR-T cell therapy

(2019) Joshua A. Hill et al.   BLOOD REVIEWS

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

(2019) Sagar Lonial et al.   LANCET ONCOLOGY

T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

(2018) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis

(2016) P. Teira et al.   BLOOD

Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients

(2014) C. Blimark et al.   HAEMATOLOGICA

Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents

(2009) Marcio Nucci et al.   CLINICAL INFECTIOUS DISEASES